APA
Siegel D., Jagannath S., Vesole D. H., Borello I., Mazumder A., Mitsiades C., Goddard J., Dunbar J., Normant E., Adams J., Grayzel D., Anderson K. C. & Richardson P. (20120713). A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. : Leukemia & lymphoma.
Chicago
Siegel David, Jagannath Sundar, Vesole David H, Borello Ivan, Mazumder Amitabha, Mitsiades Constantine, Goddard Jill, Dunbar Joi, Normant Emmanuel, Adams Julian, Grayzel David, Anderson Kenneth C and Richardson Paul. 20120713. A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. : Leukemia & lymphoma.
Harvard
Siegel D., Jagannath S., Vesole D. H., Borello I., Mazumder A., Mitsiades C., Goddard J., Dunbar J., Normant E., Adams J., Grayzel D., Anderson K. C. and Richardson P. (20120713). A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. : Leukemia & lymphoma.
MLA
Siegel David, Jagannath Sundar, Vesole David H, Borello Ivan, Mazumder Amitabha, Mitsiades Constantine, Goddard Jill, Dunbar Joi, Normant Emmanuel, Adams Julian, Grayzel David, Anderson Kenneth C and Richardson Paul. A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. : Leukemia & lymphoma. 20120713.